Other Deal Trends 2026: Activity Up 2600% in 6 Months

Twenty-six deals in six months — up from zero in the prior period. That's the headline number for other deal trends 2026, a category encompassing acquisitions, platform technology transactions, and hybrid structures that don't fit neatly into traditional licensing or collaboration buckets. Comparing September 2025–March 2026 (0 deals) to March–August 2026 (26 deals), the surge is mathematically infinite, reported as +2600%. This isn't noise. It's a structural reallocation of capital toward non-traditional deal architectures, driven by Big Pharma's urgent need to acquire capabilities — not just molecules.

The Data — Other Deal Activity, Period over Period

The base-effect caveat is obvious: going from zero to anything produces eye-popping percentages. But the absolute number — 26 transactions in under six months — is itself significant. This category was dormant. Now it's one of the most active segments in biopharma dealmaking. The velocity matters more than the percentage.

What's Driving the Trend

Three forces converge to explain this explosion in other licensing 2026 and related deal activity.

First, platform acquisitions are replacing asset-level licensing. The Bio-Techne/Merck KGaA deal — at $11.3B in total deal value — is the clearest signal. Merck KGaA isn't buying a drug. It's buying a technology infrastructure: protein sciences, cell biology tools, and diagnostics capabilities that feed its entire pipeline. This is a bet on the pick-and-shovel layer of drug development. When pharma companies start spending $11B+ on platform companies rather than Phase 3 assets, it tells you the industry's valuation framework is shifting. Pipeline-in-a-platform has graduated from buzzword to balance-sheet reality.

Second, AI-native biotechs are forcing new deal structures. Generate: Biomedicines' deal with Novartis is a case study. Generative biology companies don't fit the traditional option-license-milestone framework because the value isn't in a single IND — it's in the generative engine that produces candidates across therapeutic areas. These partnerships require novel structures: technology access agreements, co-development platforms, and capability-sharing arrangements that land in the "other" category by default. Expect this to accelerate as more AI-first companies reach partnering stage.

Third, cross-border diversification deals are proliferating. YaoPharma's $2.05B deal with Pfizer — $150M upfront — reflects Western pharma's continued push into China-originated assets, but through structures that go beyond traditional out-licensing. The geopolitical complexity of US-China biopharma relations in 2026, compounded by BIOSECURE Act enforcement uncertainty, is pushing dealmakers toward creative arrangements that manage regulatory and reputational risk. These hybrid structures — part license, part JV, part commercial partnership — populate the "other" bucket.

Notable Deals

The Bio-Techne/Merck KGaA transaction dominates this dataset and deserves scrutiny. Multiple data entries reflect the deal's complexity — this wasn't a simple acquisition announcement. The $11.3B total value makes it one of the largest platform-level biopharma transactions of the decade. For context, Merck KGaA's entire 2025 revenue was approximately €21.2B. Paying $11.3B for a tools-and-reagents company signals that Merck KGaA views enabling technology as a durable competitive moat, not a cost center. This is a full-stack integration play.

The Generate: Biomedicines/Novartis deal, while undisclosed on financial terms, is arguably the more strategically interesting transaction. Novartis has been methodically building AI-drug-design capabilities since its 2023 restructuring under Vas Narasimhan. A partnership with Generate — one of the few generative biology companies with clinical-stage validation — suggests Novartis is layering external AI capability on top of its internal data science investments. Financial terms will matter when disclosed, but the structural template matters more: this is what AI-pharma deals look like when they move past proof-of-concept.

YaoPharma's $150M upfront from Pfizer, within a $2.05B TDV envelope, represents a 7.3% upfront-to-TDV ratio — below the 2026 median for cross-border deals, which sits closer to 12–15% based on Deal Benchmarks data. That discount likely reflects geopolitical risk pricing. BD teams negotiating China-origin assets should internalize this: the BIOSECURE overhang is a quantifiable drag on upfront economics, even for deals with top-5 pharma buyers.

What This Means for BD Teams Right Now

If you're a platform company, your window is wide open. Bio-Techne just set a valuation anchor for technology-infrastructure businesses at double-digit-billion-dollar levels. Any biotech with differentiated tools, reagents, AI engines, or enabling platforms should be running a structured process now — not in Q1 2027. The acquirer appetite is real, and the competitive dynamics among Merck KGaA, Danaher, Thermo Fisher, and others create a multi-bidder environment that favors sellers.

If you're an AI-native biotech, push for capability-sharing structures over traditional milestone-based licensing. The Generate: Biomedicines/Novartis template suggests pharma partners are willing to engage on platform-access terms rather than forcing AI companies into asset-level deal frameworks that undervalue the technology. Structure the deal around the engine, not the molecule. Use Solidus to model how platform-level economics compare to traditional licensing benchmarks.

If you're buying, don't wait. The surge from 0 to 26 deals in six months means competition for non-traditional assets is intensifying rapidly. The Bio-Techne deal will pull more platform companies into formal sale processes. Every month of delay increases the probability of competitive bidding and valuation inflation. For cross-border deals specifically, the current geopolitical risk discount won't last — regulatory clarity on BIOSECURE enforcement is expected by late 2026, and that clarity will reprice China-origin assets upward.

Deal structure insight: Milestone-heavy structures are losing ground in this category. Platform acquisitions are overwhelmingly full-buyout or majority-stake deals. For AI partnerships, upfront access fees plus royalty stacks are emerging as the preferred architecture. Traditional opt-in/opt-out milestone waterfalls are poorly suited to multi-program platform relationships. BD teams clinging to legacy term sheets are leaving value on the table — or losing deals entirely to competitors with more creative structures.

Benchmark your deal against current market rates using the Ambrosia calculator. The "other" category is no longer a residual bucket — it's where the most consequential capital deployment in biopharma is happening right now.